Inactive Instrument

Nova Pharma Solutions

NPS

MYL03006O003

Nova Pharma Solutions Berhad Announces Single-Tier Interim Dividend for the Financial Year Ending 31 December 2019, Payment Date of 17 Jan. 2020

December 24, 2019 at 05:20 pm

Nova Pharma Solutions Berhad announced Single-tier Interim Dividend of 0.20 sen per share tax exempt for the financial year ending 31 December 2019. Ex-Date of 02 Jan. 2020, Entitlement date of 03 Jan. 2020 and Payment Date of 17 Jan. 2020.

Latest news about Nova Pharma Solutions

Nova Pharma Solutions Berhad Announces Interim Single-Tier Dividend for the Financial Year Ending 31 December 2023, Payable on 15 September 2023	17/08/23	CI
Nova Pharma Solutions' Profit, Revenue Rise in H1	16/08/23	MT
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2023	15/08/23	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Full Year Ended December 31, 2022	20/02/23	CI
Nova Pharma Solutions Berhad Proposes Interim Single-Tier Dividend for the Financial Year Ending 31 December 2022	23/08/22	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2022	22/08/22	CI
67,054,279 Ordinary Shares of Nova Pharma Solutions Berhad are subject to a Lock-Up Agreement Ending on 9-MAR-2022.	08/03/22	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Full Year Ended December 31, 2021	23/02/22	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2021	27/08/21	CI
Nova Pharma Solutions Berhad entered into an agreement to acquire remaining 49% stake in NOVA HITECH SOLUTIONS SDN. BHD from ACARA JUARA SDN BHD for MYR 0.05 million.	29/10/20	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2020	07/08/20	CI
Nova Pharma Solutions Berhad Appoints Mr. Ng Tik Hwa as Independent and Non Executive Director	01/07/20	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Full Year Ended December 31, 2019	21/02/20	CI
Nova Pharma Solutions Berhad Announces Single-Tier Interim Dividend for the Financial Year Ending 31 December 2019, Payment Date of 17 Jan. 2020	24/12/19	CI
Nova Pharma Solutions Berhad Approves Interim Single- Tier Dividend for the Financial Year Ending 31 December 2019	05/12/19	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2019	06/08/19	CI
Nova Pharma Solutions Berhad Announces Final Single Tier Dividend for the Financial Year Ended 31 December 2018, Payable on 08 August 2019	27/06/19	CI
Nova Pharma Solutions Berhad Announces Incorporation of Nova Incorporation of Hitech Solutions Sdn Bhd	12/06/19	CI
Nova Pharma Solutions Berhad Announces Joint Venture Cum Shareholders Agreement with Acara Juara Sdn Bhd	26/05/19	CI
Nova Pharma Solutions Berhad Proposes Final Single Tier Dividend, Payable on 08 August 2019	20/05/19	CI
Nova Pharma Solutions Berhad Announces Resignation of Tan Hong Eng as Executive Director	01/05/19	CI
67,030,228 Ordinary Shares of Nova Pharma Solutions Berhad are subject to a Lock-Up Agreement Ending on 9-MAR-2019.	08/03/19	CI
NOVA PHARMA SOLUTIONS BERHAD Recommends Final Single-Tier Dividend for the Financial Year Ended December 31, 2018	20/02/19	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Full Year Ended December 31, 2018	20/02/19	CI
Nova Pharma Solutions Berhad Announces Single-Tier Interim Dividend for the Year Ending 31 December 2018, Payable on 18 January 2019	12/12/18	CI

Chart Nova Pharma Solutions

Duration

Period

More charts

Company Profile

Nova Pharma Solutions Berhad is a Malaysia-based company, which is engaged in the business of provision of technical documentation, validation, and project execution in the pharmaceutical and biological industries. It operates through four segments: Design, Post Design, engineering, procurement, construction, and commissioning (EPCC) and Other Support. The Design segment comprise conceptual designs which include user requirement specification, capacity analysis and process scheduling with detailed costing, list of deliverables, details specification of various equipmentâs. The Post Design segment comprise tendering and procurement support as well as construction management of plant. The EPCC segment comprise of works and services pertaining to engineering, procurement, construction, and commissioning for advanced technology facilities. The Other Support segment comprise of services to assist customer in the manufacturing practice document review and gap analysis and assessment.

Sector

Construction & Engineering

Calendar

20/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Construction & Engineering

	1st Jan change	Capi.
VINCI	+1.67%	70.75B
LARSEN & TOUBRO LIMITED	-7.25%	53.96B
QUANTA SERVICES, INC.	+25.17%	39.55B
CHINA STATE CONSTRUCTION ENGINEERING CORPORATION LIMITED	+13.93%	31.18B
FERROVIAL SE	+4.72%	27.96B
CHINA RAILWAY GROUP LIMITED	+17.96%	20.94B
WSP GLOBAL INC.	+17.09%	19.65B
EMCOR GROUP, INC.	+76.98%	17.97B
CHINA COMMUNICATIONS CONSTRUCTION COMPANY LIMITED	+32.47%	17.38B

Other Construction & Engineering